PMID- 10433806
OWN - NLM
STAT- MEDLINE
DCOM- 19990921
LR  - 20191210
IS  - 1043-4666 (Print)
IS  - 1043-4666 (Linking)
VI  - 11
IP  - 8
DP  - 1999 Aug
TI  - In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus 
      infection.
PG  - 593-9
AB  - Interleukin-18 (IL-18), originally called interferon-gamma (IFN-gamma)-inducing 
      factor is a novel cytokine which exhibits pleiotropic immunomodulatory activities 
      such as the activation of natural killer (NK) cells and cytotoxic T lymphocytes 
      (CTL). In this study, the efficacy of IL-18 on viral infection in mice was 
      investigated. IL-18 treatment significantly suppressed pock formation on the 
      tails of BALB/c mice inoculated intravenously with vaccinia virus when the 
      cytokine was administered intraperitoneally on days 0, 2 and 4 after infection. 
      Sequentially, NK and CTL activity of the infected mice were significantly 
      augmented by IL-18 injection. The in vivo anti-vaccinia virus activity of IL-18 
      was only partially inhibited by treating the infected mice with anti-asialo GM1 
      antibody. When infected mice were injected with anti-IFN-gamma antibody only, 
      severe deterioration of health and significant body weight loss were observed, 
      suggesting that IFN-gamma is very important in protecting mice against vaccinia 
      virus infection. Interestingly, IL-18 injection visibly improved the severe 
      vaccinia virus-induced symptoms in mice treated with anti-IFN-gamma antibody, 
      even though a pivotal involvement of IFN-gamma in IL-18-mediated anti-vaccinia 
      virus effect is not yet determined. Taken together, these results indicate that 
      the IL-18-elicited anti-vaccinia virus effect in the acute phase of infection 
      would be raised by the sum of various host defence mechanisms including NK cells 
      and CTL, and not from a specific immunocompetent cell population or effector 
      molecule.
CI  - Copyright 1999 Academic Press.
FAU - Tanaka-Kataoka, M
AU  - Tanaka-Kataoka M
AD  - Fujisaki Institute, Hayashibara Biochemical Laboratories Inc., 675-1 Fujisaki, 
      Okayama, 702-8006, Japan.
FAU - Kunikata, T
AU  - Kunikata T
FAU - Takayama, S
AU  - Takayama S
FAU - Iwaki, K
AU  - Iwaki K
FAU - Ohashi, K
AU  - Ohashi K
FAU - Ikeda, M
AU  - Ikeda M
FAU - Kurimoto, M
AU  - Kurimoto M
LA  - eng
PT  - Journal Article
PL  - England
TA  - Cytokine
JT  - Cytokine
JID - 9005353
RN  - 0 (Antibodies)
RN  - 0 (Antiviral Agents)
RN  - 0 (Interleukin-18)
RN  - 0 (Recombinant Proteins)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Antibodies/pharmacology
MH  - Antiviral Agents/*therapeutic use
MH  - Cell Line
MH  - Chlorocebus aethiops
MH  - Cytotoxicity, Immunologic
MH  - Female
MH  - Interferon-gamma/immunology/*physiology
MH  - Interleukin-18/*therapeutic use
MH  - Killer Cells, Natural/*immunology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Recombinant Proteins/therapeutic use
MH  - Vaccinia/*immunology/prevention & control
MH  - Vaccinia virus/growth & development
MH  - Vero Cells
MH  - Weight Loss
EDAT- 1999/08/06 00:00
MHDA- 1999/08/06 00:01
CRDT- 1999/08/06 00:00
PHST- 1999/08/06 00:00 [pubmed]
PHST- 1999/08/06 00:01 [medline]
PHST- 1999/08/06 00:00 [entrez]
AID - S1043-4666(98)90453-7 [pii]
AID - 10.1006/cyto.1998.0453 [doi]
PST - ppublish
SO  - Cytokine. 1999 Aug;11(8):593-9. doi: 10.1006/cyto.1998.0453.